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Here, we report on genetically engineered, propagation-incompetent influenza A virus (IAV) particles, so-called
defective interfering particles (DIPs) that have been suggested as a promising novel antiviral agent. Typically,
IAV DIPs harbor a large internal deletion in one of their eight genomic viral RNA (vRNA) segments. Further,
DIPs are capable of hijacking cellular and viral resources upon co-infection with fully infectious standard virus
(STV), resulting in an antiviral effect. Besides this replication interference, DIP infection also stimulates innate
immunity, adding to the antiviral efficacy.
So far, DIPs were produced in embryonated chicken eggs. To improve scalability and flexibility of processes as
well as to increase product quality, we established a cell culture-based DIP production system [1,2]. This
includes the development of a genetically engineered virus-cell propagation system that allows production of
DIPs without the need to add infectious STV to complement missing gene functions of DIPs. Specifically, the
MDCK suspension cell line generated expresses the PB2 protein [2], encoded by segment 1 (S1) of IAV, which
is not expressed by “DI244” - a prototypic, well-characterized DIP harboring a deletion in S1. Using this cell
culture-based production process in batch [2,3] and perfusion mode [4] at laboratory scale, we show that we can
achieve very high DI244 titers of up to 2.6E+11 DIPs/mL. Infections of mice demonstrated that intranasal
administration of the produced DI244 material resulted in no apparent toxic effects and in a full rescue of mice
co-treated with an otherwise lethal dose of IAV [2].
Further, we screened for DIPs with improved efficacy than DI244. For instance, we conducted semi-continuous
propagation DIPs and STVs in shake flasks for 21 d [5]. Thus, DIPs were exposed to alternating selection
pressures for accumulation of highly interfering DIPs. By next-generation sequencing, we identified DIPs that
accumulated to high fractions toward the end of cultivation. Using reverse genetics, corresponding purely clonal
candidate DIPs were reconstituted that indeed showed a superior in vitro interfering efficacy than DI244 [5].
In addition, we recently discovered a yet-unrecognized novel type of DIP using our platform for single-cell
analysis of virus replication [6]. Instead of a large internal deletion, the novel DIP (termed “OP7”) showed a
significant number of nucleotide substitutions in the genomic S7 vRNA [7]. Intriguingly, OP7 showed a superior
in vitro and in vivo interfering efficacy than conventional IAV DIPs, e.g. DI244 [2,8,9]. Next, we set up a highyield cell culture-based production process for OP7 in batch mode [8]. As with DI244, administration of the
produced OP7 resulted in no toxic effects and a full rescue upon lethal STV challenge in mice [8].
Finally, we recently demonstrated that IAV DIPs even exert an antiviral effect against SARS-CoV-2 replication,
as shown by in vitro experiments using human lung cells [9]. Here, our results suggest the unspecific stimulation
of innate immunity by IAV DIPs as a major contributor. Exploring the antiviral effect of IAV DIPs against yellow
fever, Zika, and respiratory syncytial virus (RSV) replication is the subject of ongoing studies.
Overall, we propose IAV DIPs as an effective antiviral agent for treatment of the influenza disease and COVID19, and potentially also for suppressing the replication of other respiratory interferon-sensitive viruses. Our
current studies focus on the elucidation of the antiviral mechanism of DIPs, the construction of genetically
engineered virus-cell propagation systems for production of DIPs with superior efficacy, and the development of
a GMP production process for DIPs aiming toward the clinic.
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